Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) Meeting Abstract
| Authors: | Daud, A.; Hamid, O.; Robert, C.; Hodi, F. S.; Wolchok, J. D.; Hwu, W. J.; Weber, J. S.; Kefford, R.; Hersey, P.; Joshua, A. M.; Joseph, R.; Gangadhar, T. C.; Dronca, R.; Patnaik, A.; Zarour, H.; Gerigich, K.; Lunceford, J.; Emacipator, K.; Dolled-Filhart, M.; Li, X.; Kang, P.; Ebbinghaus, S.; Ribas, A. |
| Abstract Title: | Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) |
| Meeting Title: | 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 50 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2014 Nov 18-21 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-11-01 |
| Start Page: | 48 |
| End Page: | 49 |
| Language: | English |
| ACCESSION: | WOS:000347755700141 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(14)70266-7 |
| Notes: | Meeting Abstract: 140 -- 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 18-21, 2014 -- Barcelona, SPAIN -- Source: Wos |
